Amy Suzon Chappell net worth and biography

Amy Chappell Biography and Net Worth

Director of BioVie

Dr. Amy Chappell joined the BioVie Board of Directors in 2025. She currently serves as Chief Medical Officer of Solaxa Inc., where her leadership is helping the company advance therapies for ataxia and nerve repair. During her tenure as Chief Medical Officer of Eliem Therapeutics, she guided programs in epilepsy and mood disorders and helped lead the company through a successful initial public offering (IPO). Previously, she spent more than 25 years at Eli Lilly & Co., contributing to multiple Food and Drug Administration (FDA) approvals, including Cymbalta® for fibromyalgia and musculoskeletal pain. Dr. Chappell is a Fellow of the American Academy of Neurology, holds numerous patents, and has authored over 100 peer-reviewed publications. She earned her BA from Antioch College and her MD from Indiana University School of Medicine.

What is Amy Suzon Chappell's net worth?: The estimated net worth of Amy Suzon Chappell is at least $1.05 thousand as of August 28th, 2026. Dr. Chappell owns 727 shares of BioVie stock worth more than $1,047 as of October 6th. This net worth evaluation does not reflect any other assets that Dr. Chappell may own. Learn More about Amy Suzon Chappell's net worth.
How do I contact Amy Suzon Chappell?: The corporate mailing address for Dr. Chappell and other BioVie executives is 680 W Nye Lane, Suite 201, Carson City, NV, 89703. BioVie can also be reached via phone at (775) 888-3162 and via email at [email protected]. Learn More on Amy Suzon Chappell's contact information.
Has Amy Suzon Chappell been buying or selling shares of BioVie?: Amy Suzon Chappell has not been actively trading shares of BioVie during the past quarter. Most recently, on Friday, August 28th, Amy Suzon Chappell bought 727 shares of BioVie stock. The stock was acquired at an average cost of $2.16 per share, with a total value of $1,570.32. Following the completion of the transaction, the director now directly owns 727 shares of the company's stock, valued at $1,570.32. Learn More on Amy Suzon Chappell's trading history.
Who are BioVie's active insiders?: BioVie's insider roster includes Amy Chappell (Director), and Joanne Kim (CFO). Learn More on BioVie's active insiders.
Are insiders buying or selling shares of BioVie?: During the last twelve months, BioVie insiders bought shares 4 times. They purchased a total of 23,280 shares worth more than $49,118.00. The most recent insider tranaction occured on August, 28th when insider Joseph M Palumbo bought 4,843 shares worth more than $10,460.88. Insiders at BioVie own 0.9% of the company. Learn More about insider trades at BioVie.
Information on this page was last updated on 8/28/2026.

Amy Suzon Chappell Insider Trading History at BioVie

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/28/2026	Buy	727	$2.16	$1,570.32	727

Amy Suzon Chappell Buying and Selling Activity at BioVie

BioVie Company Overview

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Today's Range

Now: $1.48

$1.44

$1.49

50 Day Range

MA: $1.69

$0.96

$2.28

2 Week Range

Now: $1.48

$0.82

$3.79

Volume

29,924 shs

Average Volume

1,613,726 shs

Market Capitalization

$12.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73